Somatrogon
Published , updated
Unassigned
New Medicines
Growth hormone deficiency in adults - long-acting formulation of somatotropin
Information
New molecular entity
Pfizer
Pfizer
Development and Regulatory status
None
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes
Category
A long-acting, proprietary formulation of somatropin, for once weekly or bi-monthly administration. Disposable pre-filled pen. The technology used to develop long-acting somatropin is based on the carboxyl terminal peptide (CTP) that has been shown to extend the active time of therapeutic proteins in the body without increasing toxicity or reducing biological activity.
Growth-hormone deficiency affected approximately 4 in 10,000 people in the European Union (EU) [3].
Growth hormone deficiency in adults - long-acting formulation of somatotropin
Subcutaneous
Growth hormone deficiency in children
Information
Licence extension / variation
Pfizer
Pfizer
Development and Regulatory status
Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes
Category
A long-acting, proprietary formulation of somatropin, for once weekly or bi-monthly administration. Disposable pre-filled pen.
Growth-hormone deficiency affected approximately 4 in 10,000 people in the European Union (EU) [1].
Growth hormone deficiency in children
Subcutaneous injection